AlmaCube

 

Embed or link this publication

Description

AlmaCube - The activities

Popular Pages


p. 1

CONFINDUSTRIA EMILIA AREA CENTRO: le imprese di Bologna, Ferrara e Modena AlmaCube the Incubator of Confindustria Emilia & University of Bologna The activities ALMA ALMACUBE L’INCUBATORE DELL’UNIVERSITA’ DI BOLOGNA

[close]

p. 2

2

[close]

p. 3

AlmaCube: a business incubator supporting the regional economy Academic spin off companies of which AlmaCube is a shareholder Start ups established by University of Bologna graduates University of Bologna SMEs - spin offs Business ideas of students and graduates from the University of Bologna AlmaCube’s facts and figures 5 7 23 39 47 59 3

[close]

p. 4

4

[close]

p. 5

AlmaCube: a business incubator supporting the regional economy AlmaCube - University of Bologna Incubator starts its activities in March of 2001 under the legal form of a non-profit consortium. In 2013 AlmaCube is transformed in a Limited Company (SRL) participated by University of Bologna and Unindustria Bologna (now Confindustria Emilia) each with a 50% shares. AlmaCube mission is to generate and accompany the business growth of innovative startups and high-tech spin-offs ideated by students, graduates and researchers from the University of Bologna. AlmaCube main services are: • Agreement with the University of Bologna to make available laboratories, instrumenta- tions and patents • Direct link with banks, business angels • General secretary services • Strategical consulting and accounts service • Support for the application in National and European calls for funding • “Fostering the growth” (one2one meetings with managers and companies related to Con- findustria Emilia as potential clients and/or partner investors) • “Business Pills” (Free training courses about marketing, finance, Industrial Property ma- nagement, business law). To reach its objectives AlmaCube has been structured in 3 different Business Units: 1. B.U. StartUps: with the aim of scouting and selecting business ideas originated from stu- dents and graduates of the University of Bologna to be trained and brought to the market 2. B.U. Corporate Accelerator: to foster and promote Open Innovation and Corporate Accele- rator processes 3. B.U. Spin-offs: to support and promote hi-tech startups originated from the results of University of Bologna Research AlmaCube has two main locations with office spaces within the University of Bologna buildings in Viale Fanin 48 and in Via Ugo Foscolo 7. In 2014, AlmaCube has been acknowledged by the Italian Ministry of Economic Development as Certified Incubator for Innovative Start-ups. AlmaCube has focused his activity on four main targets: • Academic spin off companies of which AlmaCube is a shareholder • Start ups established by University of Bologna graduates • Small companies -spin offs of the University of Bologna • Business ideas of students and graduates from the University of Bologna Rebernig Supervision, Condomani and Webees have completed the AlmaCube three years incubation program and now have established their headquarters in Bologna. Until now AlmaCube has had two successful exits with Miamed Ltd and MindIt srl 5

[close]

p. 6

MiaMed was a spin-off of the University of Bologna established in 2014 as LTD under the American Law. From the MiaMed foundation, AlmaCube holds 5% of the company shares. The spin off aimed to develop a patent owned by the University of Bologna. In July 2016, the company MiaMed has been acquired by Amicus Therapeutics, a global biotechnology company Nasdaq listed. The total value of the acquisition was $6.5 million. AlmaCube gained from the transaction $ 94.521,76 in cash and 42.756 in Amicus stocks. MindIt IT is a spin-off of the University of Bologna established in May 2017. The Company is active in the machine learning and optimization techniques to support industrial entities. Last October AlmaCube left the company selling its shares: the return on capital invested has been multiplied by 15. 6

[close]

p. 7

CONFINDUSTRIA EMILIA AREA CENTRO: le imprese di Bologna, Ferrara e Modena Academic spin off companies of which AlmaCube is a shareholder ALMA ALMACUBE L’INCUBATORE DELL’UNIVERSITA’ DI BOLOGNA

[close]

p. 8

ALMAPLASMA SRL Together in the future! Company Profile Date of Constitution: May 2013 Product Launch Date: February 2017 (AlmaPLUS) Website: www.almaplasma.com Industry/sector: Atmospheric plasma processes and applications N. Founders: 8 (7 individuals and AlmaCube with a 10% of share capital) Short description AlmaPlasma s.r.l. (AP), spin-off of Università di Bologna, offers research oriented, lab-scale, customized and fully automated atmospheric plasma systems supporting processes such as materials treatments and decontamination. AP also supports the design and realization of up-scaled plasma systems, implementable in production lines. Economic and Financial Information Revenue 2016: 200.000 € Revenue 2017: 300.000 € Equity: 10.000 € Product/Service In 2017, AP launched on the market the AlmaPLUS (Plasma Laboratory Unified System), a powerful and versatile research tool where all the components required to explore a great variety of plasma-assisted processes can be integrated, and the AlmaPULSE, a pulse generator specifically designed for plasma applications. The company also supports the design and realization of up-scaled plasma systems, implementable in production lines for applications such as decontamination, surface modification, deposition of coatings (e.g. antimicrobial, barrier). Contact Vittorio Colombo E-mail: vittorio.colombo@almaplasma.com Mobile: +39 3204379910 8

[close]

p. 9

Customer Problem Atmospheric plasma technology offers innovative and cost–effective solutions for material processing in several applications, among which: surface modification of thermosensitive materials (e.g. PE, PP, HDPE,…); antimicrobial treatments (e.g. food and packaging sanitation); deposition of coatings with functional properties (e.g. antimicrobial, biocompatible, barrier, antifouling); treatment of biological tissues (e.g. skin decontamination); synthesis of nanoparticles. Target Market Target market of AlmaPlasma’ lab-scale system, AlmaPLUS, are private and public research institutes all over the word that want to acquire the necessary instrumentation to investigate the field of cold atmospheric pressure plasma applications. The design and engineering services the development, realization, analysis and optimization of novel plasma systems are instead more oriented to national and international companies willing to implement plasma technology in their productive lines. Business Model AlmaPlasma s.r.l. aims to reach through the consulting activity all the companies potentially interested in the field of industrial and medical applications of plasmas. The main target is to introduce on the market new processes and systems based on plasma technology in order to generate an income from the production and assistance on these systems. Meanwhile the sale of plasma lab-scale systems will provide additional income while favoring the discovery and development of new possible plasma applications, increasing the potential target market. Competitive Advantage AlmaPlasma s.r.l. aims to reach through the consulting activity all the companies potentially interested in the field of industrial and medical applications of plasmas. The main target is to introduce on the market new processes and systems based on plasma technology in order to generate an income from the production and assistance on these systems. Meanwhile the sale of plasma lab-scale systems will provide additional income while favoring the discovery and development of new possible plasma applications, increasing the potential target market. 9

[close]

p. 10

MHEALTH TECHNOLOGIES SRL Company Profile Date of Constitution: July 2014 Product Launch Date: July 2017 Website: www.mhealthtechnologies.it Industry/sector: eHealth, mobile Health N. Founders: 9 (8 Individuals and AlmaCube with a 8% of share capital) N. Employees: 2 Short description mHealth Technologies s.r.l. is a spin-off of the University of Bologna born in 2014 following successful experiences matured in national and international projects. We are a team of expert researchers in the fields of movement analysis, signal processing, algorithm development, wearable sensors, mobile systems, and data mining. Economic and Financial Information Revenue 2017: 25.000 € Revenue 2018 (target): 100.000 € Equity: € 20.000 Product/Service Our solutions, all marked as Medical Devices, satisfy all needs deriving from movement disorders thanks to a simple combination of wearable inertial sensors, signal processing algorithms and smartphone apps. Every product has been developed in close collaboration with specialized professionals and patients.We provide two main products: 1. mTUG and mSWAY: an Evidence Based Medicine systems for an objective assessment of the motor performance. 2. Gait Tutor: a wearable rehabilitation solutions for the restoration of the motor function. Contact Carlo Tacconi E-mail: carlo.tacconi@mhealthtechnologies.it Mobile: +39 3398590582 10

[close]

p. 11

Customer Problem Two main problems has been identified: 1.Today, Functional assessment is performed by means of clinical scales: •There is a strong needs to implement the Evidence Based Medicine (EBM) in clinical practice (i.e. Timed Up and Go, Static Posturography, 10 meter walking, etc.) 2.Today, Gait rehabilitation is usually performed by a physioterapist in the clinical environment: •There is a strong needs to reduce the healthcare system’s costs providing an autonomous system able to assist subject during gait rehabilitation, both in the clinical and in the home environment. Target Market We have two kind of final users (i.e. all the following stats are focused for the EU market): 1. Clinicians/Medical Doctors: a. Neurologist. Potential target: 50K b. Geriatrician. Potential target: 14K c. Physioterapist. Potential target: 500K 2. Patients: a. Parkinson Disease patient. Potential target: 1Mln patients b. Stroke patient. Potential target: 400K new patient each year Business Model Potential buyer: Private or Public hospitals, medical Doctors, patients Sales strategy: • Initial Target: Private and Public Referral Hospitals, opinion-leader specialized in functional evaluation and/or rehabilitation of PD and Ictus patients Sales Channel: Distributors with an already existing network on the initial target Sales methods : Direct sale: • ASP € 4000 for functional assessment system • ASP € 5000 for rehabilitation system Competitive Advantage Our competitors in the field of functional assessment provides systems not easy and rapid to be used in the clinical practice, where usability and time constraint are crucial. We provide rapid, reliable, and objective medical device for the clinical practice. Our competitors in the field of motor rehabilitation mainly provides systems based on treadmill, to be used in the gym environment. We provide the first wearable medical device aimed at gait rehabilitation on a mobile platform to be used everywhere at any time. 11

[close]

p. 12

NEXTEMA SRL Company Profile Date of Constitution: September 2015 Product Launch Date: September 2016 Website: www.nextema.com Industry/sector: Mechanical components N. Founders: 9 (8 individuals and AlmaCube with a 10% of capital share) N. Employees: 1 Short description Nextema Srl is a spin-off company of the University of Bologna. Nextema’s mission is to create faster, more flexible and more economically viable manufacturing processes for mechanical components by combining existing innovation drivers with new functionalities, greater process effectiveness and adaptability features. Nextema also aspires to design and engineer technical solutions based on new smart materials and Economic and Financial Information Capital Seeking: € 300.000 Revenue 2017: € 500.000 Revenue 2018 (target): € 1.200.000 Equity: 10.000 € Product/Service Nextema provides innovative technological services including design and development of laser devices for surface treatment of mechanical parts, engineering consulting for additive manufacturing of metal alloys via laser melting. Nextema provides engineering services for process optimisation. Nextema laser treatment systems can be easily integrated in existing production facilities. Contact Rosario Squatrito E-mail: rosario.squatrito@nextema.com Mobile: +39 39299127 12

[close]

p. 13

Customer Problem Laser heat treatment is an innovative localised surface hardening process characterised by high quality and versatility, destined to substitute most existing heat treatment techniques for surface hardening. Nextema quickly treats components of any size, weight or complexity, including difficult-to-access surfaces, with contained thermal distortion and no necessity for cooling fluids. Treatment of surfaces that would be inaccessible with induction or other hardening processes with a Real-time control of treatment width. Target Market Nextema operates in the mechanical component production market, providing advanced manufacturing systems based on client-specific needs. Its services cover a wide range of clients, from suppliers to stakeholders of different industrial fields including automotive, packaging, biomedical and cosmetic. Business Model Nextema can provide technical support for companies during the setup, commissioning and optimisation of new laser processes, as well as research and guidance in the choice of new and better suited materials in the field of laser surface treatments. Heat treatment can also be performed in-house in Nextema as well as design, personalisation and setup of client-specific laser systems for new processes. Nextema offers consulting and training services for the design and manufacturing of metallic components with powder-bed selective laser melting (SLM) additive manufacturing by direct deposition (AM). Competitive Advantage Extremely limited geometric and dimensional changes, even for complex components Online process temperature monitoring treatment with an optical pyrometer. Treatment of surfaces that would be inaccessible with induction or other hardening processes Constant hardened depth throughout the entire treated zone. Real-time control of treatment width. Constant hardness throughout the treated thickness. 13

[close]

p. 14

OACP SRL Company Profile Date of Constitution: June 2017 Product Launch Date: July 2017 Website: www.oacp.it Industry/sector: Biotech N. Founders: 7 (6 individuals and AlmaCube with a 10% of share capital) Short description OaCP Srl Oncology and Cytogenetic Products is a company active in the advanced diagnostics and research in many areas of application: biomedical, biotechnology, pharmaceutical, public health, universities and institutions, public and private, with a new generation of diagnostic and therapeutic purposes. OaCP Srl aims to become a reference point for Fluorescent In Situ Hybridization (FISH) diagnostics and research of tomorrow. Economic and Financial Information Capital Seeking: € 600.000 Investors: Sosv - Rebelbio Revenue 2018 (target): € 130.000 Equity and seed capital: € 122.000 Product/Service 1. Rapid-ISH Integra: a reagent for FISH to be added to molecular probe to reduce the total test time (from the slide to the diagnosis) to only 160 minutes while maintaining the quality of the test. 2. Rapid-ISH Integra Plus: a reagent for Fast FISH to be added to the molecular probe, while maintaining the quality of the test allows to reduce the total cost up to - 50% (TAT 2 hours). Particularly suitabile for cerbral and pulmonary tissue. 3. Rapid-ISH Integra Recovery: a reagent for in situ hybridizations (ISH) to be added to the molecular probe, while maintaining the quality of the test allows to reduce the total cost up to -50% (TAT 2 hours). Particularly suitable for retreatment of specimen previously non-diagnostic. 4. Smart-ISH Solve: a buffer for in situ hybridizations to be added to the molecular probe, while maintaining the quality of the test allows to reduce the total cost up to -50%. Contact Francesco Villa E-mail: f.villa@oacp.it Mobile: +39 3334010852 14

[close]

p. 15

Customer Problem Among the many miseries cancer brings, the anguish of the waiting for a diagnosis is one of the worst. We kill the some of this misery by majorly reducing the time for diagnostic tests, which also makes diagnostic labs more productive and profitable. OaCP, incorporated in 2017 has developed and patented proprietary reagents that act directly on DNA radically increasing the efficiency of genetic tests for cancer diagnosis and also potentially speeding up a variety of other DNA processes in industry. Target Market Our target market is the molecular in vitro diagnostics (IVD). OACP objective sector is the European in situ hybridization segment (considering Italy, Italy, France, Germany, Spain, UK) that has a value of $150M. The In situ hybridization (ISH) market reaches a total value of $551M (CAGR 5.8%) worldwide, with a forecast of $739.9M in 2021. The market is dominated by a few large companies (Roche-Qiagen-Abbott) and it is characterized by the rapid growth of small companies. The Global IVD market also includes technologies that could be applied to the genome sequencing, blood donor screening and infections. Business Model We sell directly to local distributors. In relation to the agreement, the distributor can provide multiple customers with related services such as promotion and marketing, storage and logistics, customer care. OACP key customers are clinicians, lab technicians, hospitals as well as patients (if the local health care system allows the choice of the patients, OACP will inform patients through online blogs, social networks, website and health magazines). Competitive Advantage We reduce the Hybridization to only 40 minutes instead 18 hours, reducing the whole test time to only 2 hours. We are cost effective, because adding our products to the lab procedure, the test will be more efficient, saving the use of other chemical reagents and probes, so saving costs. 15

[close]

Comments

no comments yet